Bank Julius Baer & Co
AUPH icon

Bank Julius Baer & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bank Julius Baer & Co’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7K Hold
3,340
– – ﹤0.01% 581
2026
Q1 		$49.5K Buy
+3,340
New +$48.8K ﹤0.01% 600

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank Julius Baer & Co's AUPH Position: Q2 2026 in Review

Bank Julius Baer & Co held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 3,340 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #581.

Bank Julius Baer & Co first reported a position in AUPH in Q1 2026 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Bank Julius Baer & Co held 3,340 shares of Aurinia Pharmaceuticals worth $56.7K as of Q2 2026.
  • Bank Julius Baer & Co left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #581 holding.
  • Bank Julius Baer & Co first reported a position in Aurinia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.